Sale and purchase of ship

H2O Innovation Announces Expiry of “Go-Shop” Period

Retrieved on: 
Friday, November 3, 2023

The “go-shop” period expired on November 2, 2023 at 11:59 p.m. (Montréal time) with no superior proposal having been received.

Key Points: 
  • The “go-shop” period expired on November 2, 2023 at 11:59 p.m. (Montréal time) with no superior proposal having been received.
  • H2O Innovation is now subject to a non-solicitation covenant with customary “fiduciary out” provisions under the terms of the Arrangement Agreement.
  • The Management Information Circular (the “Circular”) and related materials for the Meeting are available under the Corporation’s profile on SEDAR+ at www.sedarplus.ca and on H2O Innovation’s website at www.h2oinnovation.com .
  • H2O Innovation has retained Kingsdale Advisors to act as proxy solicitation agent and to respond to inquiries from Shareholders.

H2O Innovation Receives Interim Order and Files Management Information Circular in Connection with Special Meeting of Shareholders

Retrieved on: 
Monday, October 30, 2023

Among other things, the Interim Order authorizes the Corporation to call, hold and conduct a special meeting (the “Meeting”) of holders (the “Shareholders”) of Shares to consider the Arrangement.

Key Points: 
  • Among other things, the Interim Order authorizes the Corporation to call, hold and conduct a special meeting (the “Meeting”) of holders (the “Shareholders”) of Shares to consider the Arrangement.
  • The Management Information Circular (the “Circular”) and related materials for the Meeting are available under the Corporation’s profile on SEDAR+ at www.sedarplus.ca and on H2O Innovation’s website at www.h2oinnovation.com .
  • H2O Innovation expects to begin the distribution and mailing of the Circular and related materials to Shareholders in the coming days.
  • Shareholders of record on October 24, 2023 will be entitled to receive notice of, and to vote at, the Meeting.

H2O Innovation Announces Meeting Updates

Retrieved on: 
Friday, October 20, 2023

The Corporation intends to hold the Acquisition Meeting to consider the Arrangement on November 28, 2023.

Key Points: 
  • The Corporation intends to hold the Acquisition Meeting to consider the Arrangement on November 28, 2023.
  • The record date for the Acquisition Meeting will be October 24, 2023.
  • The Corporation announced today that it is postponing until December 22, 2023 its annual meeting of shareholders previously scheduled to be held on December 5, 2023 (the “Annual Meeting”).
  • The record date of October 26, 2023 for the Annual Meeting will remain the same, and meeting materials will be sent to shareholders of record in due course.

Velan Shareholders Approve Acquisition by Flowserve

Retrieved on: 
Friday, May 5, 2023

At the Meeting, Velan Shareholders carrying an aggregate of 82,540,128 votes, representing approximately 98.44% of votes entitled to be cast at the Meeting, were represented virtually or by proxy at the Meeting.

Key Points: 
  • At the Meeting, Velan Shareholders carrying an aggregate of 82,540,128 votes, representing approximately 98.44% of votes entitled to be cast at the Meeting, were represented virtually or by proxy at the Meeting.
  • The Arrangement remains subject to the approval of the Superior Court of Québec and the satisfaction or waiver of other customary closing conditions, including the regulatory approvals and clearances.
  • The Court hearing for the final order to approve the Arrangement is expected to take place on May 16, 2023 and the completion of the Arrangement is now expected to occur in the third quarter of 2023 (calendar year).
  • Further information regarding the Arrangement can be found in the management information circular filed by Velan on April 4, 2023, which is available at https://www.velan.com/en/company/investor_relations and under Velan’s profile on SEDAR at www.sedar.com .

HSBC SFH (France): Update on Potential Sale of HSBC SFH (France)

Retrieved on: 
Friday, April 14, 2023

The Transaction is structured such that it may proceed even if the relevant conditions to transfer HSBC SFH are not satisfied.

Key Points: 
  • The Transaction is structured such that it may proceed even if the relevant conditions to transfer HSBC SFH are not satisfied.
  • Under the terms of the Framework Agreement, the Purchaser is required to use its best efforts to obtain this approval.
  • HSBC SFH (France) is a funding vehicle used by HSBC Continental Europe for the issuance of covered bonds backed by mortgage loans issued by HSBC Continental Europe.
  • Headquartered in Paris, HSBC Continental Europe is an indirectly held subsidiary of HSBC Holdings plc.

Cash Tender Offer for 7.00% BellSouth Debentures, Corporate-Backed Trust Securities, Symbol KTBA (CUSIP No. 22080E205) at $19.00 per Certificate

Retrieved on: 
Wednesday, February 1, 2023

The terms and conditions of the Tender Offer are described in the Purchaser's Offer to Purchase dated January 30, 2023 (the "Offer to Purchase") and the related Letter of Transmittal (the "Letter of Transmittal").

Key Points: 
  • The terms and conditions of the Tender Offer are described in the Purchaser's Offer to Purchase dated January 30, 2023 (the "Offer to Purchase") and the related Letter of Transmittal (the "Letter of Transmittal").
  • $19.00 Cash Tender Offer for KTBA Securities, 7.00% CorTS Trust for BellSouth Certificates
    The Tender Offer will expire at 5:00p.m.
  • The Tender Offer is subject to the conditions in the Offer to Purchase and the Letter of Transmittal.
  • Provided that the conditions to the Tender Offer have been satisfied or waived, payment for the Certificates purchased in the Tender Offer will be made on or about March 17, 2023.

FP Credit Partners II, L.P. and FP Credit Partners Phoenix II, L.P. Commence Tender Offer for up to 7,500,000 Class A Ordinary Shares of Pathfinder Acquisition Corporation

Retrieved on: 
Monday, December 5, 2022

Holders interested in tendering their Class A Shares must do so in accordance with the procedures set forth in the Offer to Purchase.

Key Points: 
  • Holders interested in tendering their Class A Shares must do so in accordance with the procedures set forth in the Offer to Purchase.
  • Copies of the Offer to Purchase, Letter of Transmittal and other related materials are available free of charge from D.F.
  • Questions regarding the Offer and requests for assistance in connection with the Offer may be directed to D.F.
  • The Offer to Purchase and related Letter of Transmittal will be made available free of charge at the SECs website at www.sec.gov.

Sprague Resources LP Announces Anticipated Closing Date of Merger with Hartree Affiliate and Intention to Delist Its Common Units

Retrieved on: 
Friday, October 21, 2022

Upon the closing of the merger on the terms and conditions set forth in the merger agreement, the Partnership will be a wholly owned subsidiary of the Purchaser.

Key Points: 
  • Upon the closing of the merger on the terms and conditions set forth in the merger agreement, the Partnership will be a wholly owned subsidiary of the Purchaser.
  • Following completion of the merger, the common units of the Partnership will cease to be listed on the NYSE and will be deregistered under the Securities Exchange Act of 1934.
  • Sprague Resources LP is a master limited partnership engaged in the purchase, storage, distribution and sale of refined petroleum products and natural gas.
  • You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

ProSomnus® Announces Availability of Insurance Reimbursement for Oral Appliance Therapy Devices in Germany

Retrieved on: 
Thursday, September 15, 2022

ProSomnus is the first manufacturer of precision, mass-customized oral appliance therapy devices to treat OSA, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes.

Key Points: 
  • ProSomnus is the first manufacturer of precision, mass-customized oral appliance therapy devices to treat OSA, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes.
  • ProSomnuss patented devices are a more comfortable and less invasive alternative to Continuous Positive Airway Pressure (CPAP) therapy, and lead to more effective and patient-preferred outcomes.
  • With more than 150,000 patients treated, ProSomnuss devices are the most prescribed oral appliance therapy in the U.S. To learn more, visit www.ProSomnus.com .
  • In May 2022, ProSomnus entered a definitive merger agreement with Lakeshore Acquisition I Corp. (Nasdaq: LAAA), a special purpose acquisition company.

ProSomnus Named to Inc. 5000 List of Fastest-Growing Companies for Fourth Consecutive Year

Retrieved on: 
Tuesday, August 16, 2022

This marks the fourth consecutive year that ProSomnus has been included in the Inc. 5000 list.

Key Points: 
  • This marks the fourth consecutive year that ProSomnus has been included in the Inc. 5000 list.
  • Companies on the 2022 Inc. 5000 list are ranked according to percentage revenue growth from 2018 to 2021.
  • The entire ProSomnus team is honored to be featured on the Inc. 5000 list for the fourth consecutive year, said Len Liptak, Co-Founder and Chief Executive Officer of ProSomnus.
  • The complete 2022 Inc. 5000 list, including an interactive database that can be sorted by industry, region, and other criteria can be found at http://www.inc.com/inc5000/2022 .